{"prompt": "['MC1752', '30', 'CTCAE', 'System/Organ/Class', 'ADVERSE', '(SOC)', 'EVENTS/SYMPTOMS', 'Avelumab', 'Delay avelumab for Grade 3.', 'Permanently discontinue for Grade 4 or recurrent Grade 3.', 'Consider skin biopsy', 'Dermatology consult', 'Rash acneiform', '1 to 2 mg/kg/day prednisone or equivalent', 'Grade 3 to 4', 'Add prophylactic antibiotics for opportunistic infections', 'If Grade 3 improves to Grade 1:', 'Taper steroids over at least 1 month; resume avelumab therapy', 'following steroids taper (for initial Grade 3).', 'If persists > 1 to 2 weeks or recurs:', 'Delay avelumab therapy', 'Consider skin biopsy', 'Consider 0.5-1 mg/kg/day prednisone or equivalent. Once', 'improving, taper steroids over at least 1 month, consider', 'Rash maculo-papular', 'Grade 1 to 2', 'prophylactic antibiotics for opportunistic infections, and', 'resume avelumab therapy following steroids taper.', 'If worsens:', 'Treat as Grade 3 to 4.', 'Delay avelumab for Grade 3.', 'Permanently discontinue for Grade 4 or recurrent Grade 3.', 'Consider skin biopsy', 'Dermatology consult', 'Rash maculo-papular', '1 to 2 mg/kg/day prednisone or equivalent', 'Grade 3 to 4', 'Add prophylactic antibiotics for opportunistic infections', 'If Grade 3 improves to Grade < 1:', 'Taper steroids over at least 1 month; resume avelumab therapy', 'following steroids taper (for initial Grade 3).', 'General disorders and', 'Infusion-related reaction', 'administration site conditions', 'Grade 1', 'Decrease the avelumab infusion rate by 50% and', 'Mild transient reaction; infusion', 'monitor closely for any worsening', 'interruption not indicated;', 'intervention not indicated', 'Infusion-related reaction', 'Temporarily discontinue avelumab infusion', 'Grade 2', 'Resume infusion at 50% of previous rate once infusion-', 'Therapy or infusion interruption', 'related reaction has resolved or decreased to at least Grade', 'indicated but responds promptly', '1 in severity, and monitor closely for any worsening', 'to symptomatic treatment (for', 'Once the avelumab infusion rate has been decreased by 50% or', 'example, antihistamines,', 'interrupted due to an infusion-related reaction, it must remain', 'NSAIDs, narcotics, iv fluids);', 'decreased for all subsequent infusions. If the subject has a', 'prophylactic medications', 'second infusion-related reaction Grade > 2 on the slower', 'indicated for < 24 h', 'infusion rate, the infusion should be stopped and the subject', 'should be removed from avelumab treatment.', 'Protocol Version Date: 21JUN2018']['MC1752', '31', 'CTCAE', 'System/Organ/Class', 'ADVERSE', '(SOC)', 'EVENTS/SYMPTOMS', 'Avelumab', 'Infusion-related reaction', 'Grade 3 or Grade 4', 'Grade 3: Prolonged (for', 'example, not rapidly', 'responsive to', 'Stop the avelumab infusion immediately and', 'symptomatic medication', 'disconnect infusion tubing from the subject', 'and/or brief interruption', 'Subjects have to be withdrawn immediately from', 'of infusion); recurrence', 'avelumab treatment and must not receive any further', 'avelumab treatment', 'of symptoms following', 'initial improvement;', 'All Grade 3 or 4 infusion reactions should be', 'hospitalization indicated', 'reported within 24 hours to EMD Serono and', 'for clinical sequelae', 'reported as an SAE if criteria are met.', 'Grade 4: Life-threatening', 'consequences; urgent', 'intervention indicated', 'Investigations', 'Aspartate aminotransferase', 'increased', 'or Alanine aminotransferase', 'increased', 'Continue avelumab therapy', 'Bilirubin increased', 'Continue liver function monitoring', 'If worsens:', 'Grade 1', 'Treat as Grade 2 or 3 to 4.', 'AST or ALT > ULN to 3.0 X', 'ULN and/or Total bilirubin >', 'ULN to 1.5 X ULN', 'Aspartate aminotransferase', 'increased', 'or Alanine aminotransferase', 'Delay avelumab therapy', 'increased', 'Increase frequency of monitoring to every 3 days.', 'Bilirubin increased', 'If returns to Grade VI 1:', 'Resume routine monitoring; resume avelumab therapy.', 'Grade 2', 'If elevation persists > 5 to 7 days or worsens:', 'AST or ALT > 3.0 to VI 5 X ULN', 'Treat as Grade 3 to 4.', 'and/or total bilirubin > 1.5 to < 3', 'x ULN', 'Aspartate aminotransferase', 'Permanently discontinue avelumab therapy', 'increased', 'Increase frequency of monitoring to every 1 to 2 days', 'or Alanine aminotransferase', '1 to 2 mg/kg/day prednisone or equivalent', 'increased', 'Bilirubin increased', 'Add prophylactic antibiotics for opportunistic infections', 'Consult gastroenterologist/ hepatologist', 'Consider obtaining MRI/CT scan of liver and liver biopsy if', 'Grade 3 to 4', 'clinically warranted', 'AST or ALT > 5 X ULN and/or', 'total bilirubin > 3 X ULN', 'Continue avelumab therapy', 'Grade 1', 'Continue renal function monitoring', 'Creatinine increased > ULN to', 'If worsens:', '1.5 X ULN', 'Treat as Grade 2 to 3 or 4.', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}